UF Innovate | Ventures

Kate Therapeutics Debuts With $51 Million Series A To Develop Next-Generation Genetic Medicines To Treat Muscle and Heart Diseases

Kate Therapeutics Inc., a next-generation gene therapy company, has emerged from stealth mode after securing a $51 million Series A financing round. The funding was co-led by Westlake Village BioPartners and Versant Ventures, with participation from Osage University Partners and UF Innovate | Ventures. Additionally, the company has granted Astellas Pharma Inc. an exclusive worldwide license to develop, manufacture, and commercialize KT430 for the treatment of X-linked myotubular myopathy (XLMTM).

IPOs Could Be Headed for a Rocky Road in 2023

Initial public offerings appear likely to remain sluggish for at least several months to start 2023, while special purpose acquisition companies, which provide businesses with alternative paths to public listings, face headwinds of their own. Hear what University of Florida professor Jay Ritter, has to say about a possible IPO drought.

UF Innovate Hosts First Fast Break Ventures Summit

Investors, innovators, and entrepreneurs convened at the University of Florida Stephen C. O’Connell Center for UF Innovate | Ventures' first-annual Fast Break Ventures Summit. Over 100 attendees met on center court for an afternoon filled with discussion on the state of venture capital in Florida and to hear pitches from six startup companies. 

Hey Founder, Here’s How To Build Your Brand

Building and establishing your personal brand is key to standing out in the current market. Your brand is your track record plus reputation—everything that people currently know you for. Here are four tangible steps to make yourself and your company stand out!

Pharmacosmos Group Acquires AbFero Pharmaceuticals, Inc.

Pharmacosmos Group, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, today announced the acquisition of UF startup AbFero Pharmaceuticals, Inc., a Boston-based, privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload.